Last $169.64 USD
Change Today +2.17 / 1.30%
Volume 490.9K
PCYC On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:01 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

pharmacyclics inc (PCYC) Key Developments

Pharmacyclics Inc. and Janssen Biotech, Inc. Announce U.S. FDA Approves IMBRUVICA (Ibrutinib) for Treatment of Waldenstrom's Macroglobulinemia

Pharmacyclics, Inc. announced that the U.S. Food and Drug Administration has granted single-agent IMBRUVICA (ibrutinib) regular (full) approval in all lines of therapy as the first and only treatment for patients with Waldenstrom's macroglobulinemia (WM), a rare, indolent type of B-cell lymphoma. This is the fourth indication for IMBRUVICA, an oral therapy, which received FDA Breakthrough Therapy Designation for this indication in February 2013. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. The approval is based on results from a multi-center, Phase II study that evaluated the efficacy and tolerability of IMBRUVICA in 63 patients with previously treated WM. In this study, IMBRUVICA demonstrated a response rate of 62% according to an Independent Review Committee. Very good partial responses (VGPR) of 11% and partial responses (PR) of 51% were observed. These responses were maintained and the median duration of response (DOR) has not been reached, with a range of 2.8+ to 18.8+ months.

Pharmacyclics, Inc. Announces Preliminary U.S. Net Product Revenue Results for the Fourth Quarter and Fiscal Year Ended December 31, 2014 and Provides U.S. Net Product Revenue Guidance for Fiscal Year 2015

Pharmacyclics Inc. provided preliminary unaudited 2014 U.S. net product revenue results For the fiscal year ended December 31, 2014, U.S. net product revenue for is expected to be approximately $492 million. For the fourth quarter of 2014, U.S. net product revenue is expected to be approximately $185 million, which would represent an approximately 31% sequential increase compared to the quarter ended September 30, 2014. For 2015, the company anticipates U.S. net product revenue of approximately $1 billion for IMBRUVICA, representing a 103% increase over the expected 2014 U.S. net product revenue.

Pharmacyclics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 02:30 PM

Pharmacyclics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 02:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Robert W. Duggan, Chairman and Chief Executive Officer.

Pharmacyclics Inc.(NasdaqGS:PCYC) added to NASDAQ Biotechnology Index

Pharmacyclics Inc. will be added to the NASDAQ Biotechnology Index.

Pharmacyclics Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Pharmacyclics Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCYC:US $169.64 USD +2.17

PCYC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celgene Corp $120.98 USD +0.11
View Industry Companies
 

Industry Analysis

PCYC

Industry Average

Valuation PCYC Industry Range
Price/Earnings 100.0x
Price/Sales 22.4x
Price/Book 17.5x
Price/Cash Flow 145.1x
TEV/Sales 21.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.